Bloodwork Before Starting Sermorelin

Why Baseline Bloodwork Matters for Sermorelin

Sermorelin is a GHRH analog, meaning it works upstream of growth hormone itself. Rather than injecting exogenous GH, sermorelin binds to receptors on the anterior pituitary and stimulates the gland to produce and release growth hormone in a pulsatile, physiologic pattern. That distinction matters for bloodwork because your pre-protocol labs establish how your GH/IGF-1 axis is functioning before you add a secretagogue signal. Without a baseline IGF-1 value, there is no way to determine whether a post-protocol reading of 250 ng/mL represents a therapeutic shift or was your starting point all along. Baseline labs also reveal conditions that would blunt sermorelin’s effect entirely, such as elevated cortisol suppressing pituitary output or undiagnosed thyroid dysfunction limiting downstream GH signaling. Dose calibration depends on knowing where you started.

What to Test Before Starting

Three biomarkers form the core of a pre-sermorelin panel, and each one tells your provider something different about your readiness for a GHRH-based protocol.

IGF-1 is the single most important baseline draw. Because sermorelin increases GH secretion, and the liver converts circulating GH into IGF-1, this marker serves as the primary gauge of therapeutic response over time. Drawing it before your first dose creates the reference point that every future lab will be measured against. An already-elevated IGF-1 at baseline may indicate that additional GH stimulation is unnecessary or that further investigation is warranted before proceeding.

Fasting Glucose should be drawn after an overnight fast. Growth hormone has well-documented effects on glucose metabolism, and sermorelin’s stimulation of GH can shift fasting glucose levels over time. A baseline reading in the impaired range changes the risk calculus of the protocol and may require tighter monitoring intervals or concurrent metabolic support.

Cortisol rounds out the baseline panel. Chronically elevated cortisol directly suppresses pituitary GH output, which means sermorelin may underperform in a high-cortisol environment. A morning cortisol draw identifies whether the hypothalamic-pituitary-adrenal axis needs to be addressed before or alongside GH optimization. If cortisol is significantly elevated, your provider may choose to normalize it first rather than layer a secretagogue on top of a suppressed pituitary.

What to Retest and When

At 4 weeks, retest GH. This is the earliest meaningful checkpoint for confirming that sermorelin is reaching the pituitary and producing a secretory response. A GH draw at this stage should reflect the pulsatile increase that distinguishes GHRH analogs from flat-curve exogenous GH administration. If GH has not moved, the dose or injection timing may need adjustment before continuing.

At 8 weeks, retest IGF-1. Because IGF-1 reflects cumulative GH exposure rather than a single pulse, it lags behind GH itself and requires more time to shift. Comparing this value to your baseline tells you whether the downstream conversion pathway is intact and whether the dose is producing a clinically meaningful change.

At 12 weeks, retest testosterone. Sermorelin-driven GH increases can influence testosterone levels over longer timeframes through its effects on gonadal function and body composition. This draw confirms whether the broader endocrine environment is shifting in the expected direction.

Bring all results to your prescribing provider before making any dose changes. Lab interpretation without clinical context leads to bad decisions.

Red Flags — When to Pause and Retest

Do not start or continue sermorelin in the presence of active malignancy. GH is a growth signal, and adding a secretagogue in that context is contraindicated. Untreated hypothyroidism will blunt the protocol’s effectiveness and should be corrected first. If you are taking glucocorticoids, be aware that they have a documented interaction with sermorelin and may reduce your GH response. Concurrent insulin use introduces a theoretical concern around altered insulin sensitivity that requires closer glucose monitoring. Obesity-related GH suppression can also limit sermorelin’s effectiveness, and your provider should factor body composition into protocol design.

How This Fits Your Broader Protocol

Sermorelin is frequently combined with other peptides in stacked protocols. If you are running a multi-compound approach, review the full sermorelin contraindications page before adding anything, and use the interaction checker to screen for compound-level conflicts. Pre-protocol bloodwork applies to the stack as a whole, not just a single peptide in isolation.